Kura Oncology, Inc.(KURA)

Description: Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule drug candidates that target cell signaling pathways, which drive the progression of various cancers. The company's lead drug candidate, tipifarnib, an inhibitor of protein farnesylation is in Phase II clinical trials used for the treatment of solid tumors, including thyroid, head, neck, urothelial carcinomas, and salivary cancers with HRAS mutations, as well as patients with peripheral T-cell lymphoma. Its product pipeline also comprise preclinical programs, such as orally-available small molecule inhibitors of extracellular-signal-regulated kinases 1 and 2, such as KO-947 and other backup compounds for the treatment of patients with activating mutations in or other dysregulation of the mitogen-activated protein kinase signaling pathway consisting of mutations in KRAS, BRAF, and NRAS; and orally available, small molecule inhibitors of the menin-MLL interaction for the treatment of patients with acute leukemias involving translocations or partial tandem duplications of the mixed lineage leukemia (MLL) gene. The company was founded in 2014 and is headquartered in La Jolla, California.

---

Keywords: Medicine Cancer Solid Tumors Oncology Lymphoma Leukemia Thyroid Carcinoma Oncogenes Signal Transduction Kras Cell Signaling Acute Leukemia Protein Kinase Blood Cancers Benzamides Mek Inhibitor Peripheral T Cell Lymphoma Mixed Lineage Leukemia Ras Subfamily Treatment Of Solid Tumors And Blood Cancers

---

Home Page: kuraoncology.com

KURA Technical Analysis

12730 High Bluff Drive
San Diego, CA 92130
United States
Phone: 858 500 8800

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)